Back to search

Article

ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclib

2025-11-29

Abstract excerpt

<h4>Background: </h4> Palbociclib, combined with endocrine therapy (ET), is widely used for hormone receptor (HR)-positive, HER2-negative advanced breast cancer, but severe neutropenia is common, particularly in Asian populations. Pharmacogenetic determinants beyond ABCB1 remain insufficiently characterized, and real-world data in Japanese patients are scarce. <h4>Methods: </h4> A total of 84 patients were inves...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0cba47c3-4b4b-5468-a951-6b307608d83d
DOI
10.22541/au.176441075.52960939/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ABCG2 genetic polymorphism as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibDOI 10.22541/au.176441075.52960939/v1
ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity
ABCG2 genetic variant as a predictor of severe neutropenia in Japanese patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with palbociclib: an exploratory real-world studySemantic proximity
Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Semantic proximity
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Semantic proximity
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.Semantic proximity
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclibSemantic proximity
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.Semantic proximity
Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.Semantic proximity
Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity
Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapySemantic proximity
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.Semantic proximity
Select a neighboring publication to make it the new centre.